Nanoemulsion containing dapsone for topical administration: A study of in vitro release and epidermal permeation

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 535-544

  Borges, Vinícius Raphael de Almeida ^a   Simon, Alice ^a   Sena, Adrian Ricardo Cuello ^a   Cabral, Lúcio Mendes ^a   de Sousa, Valéria Pereira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Dapsone; Nanoemulsion; Permeation; Release; Topical

Indexed keywords

1 METHYL 2 PYRROLIDINONE; DAPSONE; MYRISTIC ACID ISOPROPYL ESTER;

ACNE; ANIMAL TISSUE; ARTICLE; CONDUCTANCE; CONTROLLED STUDY; DROPLET SIZE; DRUG DETERMINATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; EAR; EPIDERMIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGUCHI MODEL; IN VITRO STUDY; LEPROSY; NANOEMULSION; NONBIOLOGICAL MODEL; NONHUMAN; PH; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; REFRACTION INDEX; SKIN PENETRATION; SKIN SURFACE; SWINE;

DAPSONE; NANOEMULSION; PERMEATION; RELEASE; TOPICAL;

ADMINISTRATION, CUTANEOUS; ANALYSIS OF VARIANCE; ANIMALS; DAPSONE; DRUG STABILITY; ELECTRIC CONDUCTIVITY; EMULSIONS; EPIDERMIS; HYDROGEN-ION CONCENTRATION; MYRISTATES; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; PYRROLIDINONES; REPRODUCIBILITY OF RESULTS; SKIN ABSORPTION; SWINE;

EID: 84873691994     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39383     Document Type: Article

References (41)

1. Sago J, Hall RP. Dapsone. Dermatol Ther. 2002;15:340-351.
2. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001;19:79-86.
3. Wakabayashi M, Fujii N, Fujimoto N, Tanaka T. Cystic acne successfully treated with diaminodiphenylsulfone. J Dermatol. 2011;38:502-504.
4. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12: 413-420.
5. Monteiro LM, Lione VF, do Carmo FA, et al. Development and in silico bioavailability studies of dapsone oral nanoemulsion systems. Int J Nanomedicine. 2012;7:5175-5182.
6. Wozel VEG. Innovative use of dapsone. Dermatol Clin. 2010;28:599-610.
7. Pupe CG, Villardi M, Rodrigues CR, et al. Preparation and evaluation of antimicrobial activity of nanosystems for the control of oral pathogens Streptococcus mutans and Candida albicans. Int J Nanomedicine. 2011;6:2581-2590.
8. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release. 2010;141:265-276.
9. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of dapsone. AAPS Pharm Sci Tech. 2008;9:47-53.
10. Saluja V, Chopra D, Singh N, Sekhon BS. Anti-inflammatory potential of dapsone loaded chitosan nanoparticles in streptozotocin-induced experimental dementia. IJPSN. 2011;4:1347-1358.
11. Zhang Y, Gao J, Zheng H, Zhang R, Han Y. The preparation of 3,5-dihydroxy-4-isopropulstilbene nanoemulsion and in vitro release. Int J Nanomedicine. 2011;6:649-657.
12. Salim N, Basri M, Rahman MB, Abdullah DK, Basri H. Modification of palm kernel oil esters nanoemulsions with hydrocolloid gum for enhanced topical delivery of ibuprofen. Int J Nanomedicine. 2012;7:4739-4747.
13. Djekic L, Primorac M. The influence of cosurfactants and oils on the formation of pharmaceutical nanoemulsions based on PEG-8 caprylic/capric glycerides. Int J Pharm. 2008;352:231-239.
14. Elshafeey AH, Kamel AO, Fathallah MM. Utility of nanosized nanoemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. Pharm Res. 2009;226:2446-2453.
15. Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release. 2010;141:277-299.
16. Nandi I, Bari M, Joshi H. Study of isopropyl myristate nanoemulsion system containing cyclodextrins to improve the solubility of 2 model hydrophobic drugs. AAPS Pharm Sci Tech. 2003;4:E10.
17. Sarkar A, Ruma Rano, Mishra KK, Sinha IN. Particle size distribution profile of some Indian fly ash-a comparative study to assess their possible uses. Fuel Process Technol. 2005;86:1221-1238.
18. US Pharmacopeia. NF-29, 34th ed. Rockville, MD: US Pharmacopeia Convention; 2011.
19. International Conference on Harmonization. Q2B. Validation of analytical procedures: Methodology. US Department of Health and Human Services Food and Drug Administration, 1996. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073384.pdf. Accessed January 6, 2013.
20. Junyaprasert VB, Boonme P, Songkro S, Krauel K, Rades T. Transdermal delivery of hydrophobic and hydrophilic local anesthetics from o/w and w/o Brij 97-based microemulsion. J Pharm Sci. 2007;10:288-298.
21. Moser K, Kriwet K, Naik A, Kalia YN, Guy RH. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm. 2001;52:103-112.
22. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Biopharm. 2001;13:123-133.
23. Draelos ZD, Carter E, Maloney JM, etal; United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439. e1-e10.
24. Jouyban A, Fakhree MAA, Shayanfar A. Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J Pharm Pharm Sci. 2010;13:524-535.
25. Zheng WW, Zhao L, Wei YM, Ye Y, Xiao SH. Preparation and the in vitro evaluation of nanoemulsion system for the transdermal delivery of granisetron hydrochloride. Chem Pharm Bull. 2010;58:1015-1019.
26. Lee PJ, Langer R, Shastri VP. Novel nanoemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm Res. 2003;20:264-269.
27. Fujii M, Koizumi A, Kinoshita Y, et al, Effect of n-methyl-2-pyrrolidone on the skin permeation of estradiol and levonorgestrel from adhesive strips prepared using Eudragit EPO. J Drug Deliv Sci Technol. 2006;16:121-125.
28. Babu RJ, Pandit JK. Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin. Drug Deliv. 2005;12:165-169.
29. Yerramsetty KM, Neely BJ, Madihally SV, Gasem KA. A skin permeability model of insulin in the presence of chemical penetration enhancer. Int J Pharm. 2010;388:13-23.
30. Kreilgaard M. Influence of nanoemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 2002;54:77-98.
31. Kogan A, Garti N. Nanoemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci. 2006;123-126:369-385.
32. Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm. 2008;360:184-190.
33. Tenjarla S. Nanoemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 1999;16:461-521.
34. Formariz TP, Urban MCC, da Silva Júnior AA, Gremião MPD, Oliveira AG. Nanoemulsions and liquid crystalline phases as drug delivery systems. Braz J Pharm Sci. 2005;41:301-313. Portuguese.
35. Dziubla TD, Torjman MC, Joseph JI, Murphy-Tatum M, Lowman AM. Evaluation of porous networks of poly(2-hydroxyethyl methacrylate) as interfacial drug delivery devices. Biomaterials. 2001;22:2893-2899.
36. Scior T, Raddatz G, Figueroa R, Roth HJ, Bisswanger HA. Molecular modeling study on dapsone and sulfonamides comparing structures and properties with respect to anti-leprosy activity. J Mol Model. 1997;3:332-337.
37. Queiroz RHC, Dreossi SA, Carvalho D. A rapid, specific, and sensitive method for the determination of acetylation phenotype using dapsone. J Anal Toxicol. 1997;21:203-207.
38. British Pharmacopoeia. The official collection of standards for United Kingdom medicinal products and pharmaceutical substances. London, UK: The Stationery Office; 2005.
39. Patel MR, Patel RB, Parikh JR, Solanki AB, Patel BG. Effect of formulation components on the in vitro permeation of microemulsion drug delivery system of fluconazole. AAPS Pharm Sci Tech. 2009;10:917-923.
40. Trommer H, Neubert RHH. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol. 2006;19:106-121.
41. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420-434.